Braveheart Bio, Inc. (BRVE)
NasdaqGM · Biotechnology
26.59
-1.08 (-3.89%)
Updated Aug 18, 5:45 PM ET
Price history
Daily closes and volume
Aug 6, 2026
7 sessions
Aug 14, 2026
About Braveheart Bio, Inc.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Company website